Synthetic Engineered RNA Molecules and Related Methods
Summary
USPTO published patent application US20260109976A1 filed by Kristine Bielecki and Devan Shah on May 28, 2025, covering heterologous engineered mRNA molecules designed to increase expression profiles. The application, assigned number 19221434 and published April 23, 2026, includes CPC classifications spanning C12N biochemistry and A61K pharmaceutical preparation categories. Patent rights, if granted, would provide exclusivity over the synthetic engineered mRNA constructs and associated production methods.
“Provided herein are heterologous engineered mRNA molecules; and methods of making and using said synthetic engineered mRNAs to increase expression profiles.”
About this source
GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 258 changes logged to date.
What changed
USPTO published patent application US20260109976A1 for heterologous engineered mRNA molecules and methods for increasing expression profiles, filed May 28, 2025 by inventors Kristine Bielecki and Devan Shah. The application is assigned number 19221434 and covers synthetic engineered RNAs with enhanced expression characteristics, classified under C12N 15/11, A61K 9/5123, A61K 31/7105, A61K 47/12, and C12N 15/10.
Companies developing mRNA-based therapeutics, vaccine platforms, or gene expression systems should monitor this application for potential freedom-to-operate implications. While the application is pending and not yet enforceable, any claims granted could affect the scope of permissible mRNA engineering activities. The filing establishes a priority date of May 28, 2025.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SYNTHETIC ENGINEERED RNA MOLECULES AND RELATED METHODS
Application US20260109976A1 Kind: A1 Apr 23, 2026
Inventors
Kristine Bielecki, Devan Shah
Abstract
Provided herein are heterologous engineered mRNA molecules; and methods of making and using said synthetic engineered mRNAs to increase expression profiles.
CPC Classifications
C12N 15/11 A61K 9/5123 A61K 31/7105 A61K 47/12 C12N 15/10
Filing Date
2025-05-28
Application No.
19221434
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.